Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma by Greuter, MJE, Eertink, JJ, Jongeneel, G, Dührsen, U, Hüttmann, A, Schmitz, C, Lugtenburg, PJ, Barrington, SF, Mikhaeel, NG, Ceriani, L, Zucca, E, Carr, R, Györke, T, Burggraaff, CN, de Vet, HCW, Hoekstra, OS, Zijlstra, JM, Coupé, VMH

Get full text

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma by Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., Boellaard, R., Zijlstra, J. M.

Get full text

The eHealth self-management application 'Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most? by van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A. P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M.

Get full text

R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study by Al‐Sarayfi, D., Brink, M., Chamuleau, M. E. D., Brouwer, R., Rijn, R. S., Issa, D., Deenik, W., Huls, G., Mous, R., Vermaat, J. S. P., Diepstra, A., Zijlstra, J. M., Meerten, T., Nijland, M.

Get full text

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients by Eertink, J.J., Burggraaff, C.N., Heymans, M.W., Dührsen, U., Hüttmann, A., Schmitz, C., Müller, S., Lugtenburg, P.J., Barrington, S.F., Mikhaeel, N.G., Carr, R., Czibor, S., Györke, T., Ceriani, L., Zucca, E., Hutchings, M., Kostakoglu, L., Loft, A., Fanti, S., Wiegers, S.E., Pieplenbosch, S., Boellaard, R., Hoekstra, O.S., Zijlstra, J.M., de Vet, H.C.W.

Get full text

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements by Eertink, J. J., Arens, A. I. J., Huijbregts, J. E., Celik, F., de Keizer, B., Stroobants, S., de Jong, D., Wiegers, S. E., Zwezerijnen, G. J. C., Burggraaff, C. N., Boellaard, R., de Vet, H. C. W., Hoekstra, O. S., Lugtenburg, P. J., Chamuleau, M. E. D., Zijlstra, J. M.

Get full text

Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients by Croese, K. J., Zwezerijnen, G. J. C., Bes, A. L., Wiegers, S. E., Heymans, M. W., Boellaard, R., Lugtenburg, P. J., Eertink, J. J., Zijlstra, J. M., Chamuleau, M. E. D.

Get full text

Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study by Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A. S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J. M., Greil, R., Feuring‐Buske, M., Markova, J., Kobe, C., Eich, H. T., Baues, C., Fuchs, M., Behringer, K., Borchmann, P.

Get full text

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group by Ferdinandus, J., Moccia, A. A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Fuchs, M., Behringer, K., Schneider, G., Rosenwald, A., Klapper, W., Eich, H. T., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A., Borchmann, P.

Get full text

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL by Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Ferdinandus, J., Fuchs, M., Rosenwald, A., Klapper, W., Eich, H., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A.

Get full text

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans by de Vries, Bart M., Golla, Sandeep S. V., Zwezerijnen, Gerben J. C., Hoekstra, Otto S., Jauw, Yvonne W. S., Huisman, Marc C., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, Willemien C., Zijlstra-Baalbergen, Josée J. M., Mesotten, Liesbet, Boellaard, Ronald, Yaqub, Maqsood

Get full text

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transp... by Kersten, Marie José, Driessen, Julia, Zijlstra, Josée M, Plattel, Wouter J, Morschhauser, Franck, Lugtenburg, Pieternella J, Brice, Pauline, Hutchings, Martin, Gastinne, Thomas, Liu, Roberto, Burggraaff, Coreline N, Nijland, Marcel, Tonino, Sanne H, Arens, Anne I J, Valkema, Roelf, van Tinteren, Harm, Lopez-Yurda, Marta, Diepstra, Arjan, De Jong, Daphne, Hagenbeek, Anton

Get full text

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma by Regelink, J C, Raijmakers, P G, Bravenboer, N, Milek, R, Hoetjes, N J, de Kreuk, A M, van Duin, M, Wondergem, M J, Lips, P, Sonneveld, P, Zijlstra, J M, Zweegman, S

Get full text

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP by Driessen, Julia, Kersten, Marie José, Visser, Lydia, van den Berg, Anke, Tonino, Sanne H., Zijlstra, Josée M., Lugtenburg, Pieternella J., Morschhauser, Franck, Hutchings, Martin, Amorim, Sandy, Gastinne, Thomas, Nijland, Marcel, Zwezerijnen, Gerben J. C., Boellaard, Ronald, de Vet, Henrica C. W., Arens, Anne I. J., Valkema, Roelf, Liu, Roberto D. K., Drees, Esther E. E., de Jong, Daphne, Plattel, Wouter J., Diepstra, Arjan

Get full text

LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY by Driessen, J., Kersten, M. J., Visser, L., van den Berg, A., Zijlstra, J. M., Tonino, S. H., Zwezerijnen, G. J., Boellaard, R., Lugtenburg, P. J., Hutchings, M., Nijland, M., Liu, R. D., Morschhauser, F., Brice, P., Gastinne, T., de Jong, D., Hagenbeek, A., Plattel, W. J., Diepstra, A.

Get full text

Risk of male breast cancer after Hodgkin lymphoma by de Vries, Simone, Krul, Inge M, Schaapveld, Michael, Janus, Cecile P M, Rademakers, Saskia E, Roesink, Judith M, Nijziel, Marten R, Bilgin, Yavuz M, Aleman, Berthe M P, van Leeuwen, Flora E

Get full text

OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study by Bromberg, J E C, Issa, S, van der Holt, B, Minnema, M C, Seute, T, Durian, M F, Cull, G, van der Poel, M W M, Stevens, W B C, Zijlstra, J M, Nijland, M, Mason, K D, Beeker, A, Brandsma, D, van den Bent, M J, Gonzalez, M, de Jong, D, Doorduijn, J K

Get full text

Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial by van der Hout, A., Jansen, F., van Uden-Kraan, C. F., Coupé, V. M., Holtmaat, K., Nieuwenhuijzen, G. A., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M.

Get full text

Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled... by van der Hout, A., van Uden-Kraan, C.F., Holtmaat, K., Jansen, F., Lissenberg-Witte, B.I., Nieuwenhuijzen, G.A.P., Hardillo, J.A., Baatenburg de Jong, R.J., Tiren-Verbeet, N.L., Sommeijer, D.W., de Heer, K., Schaar, C.G., Sedee, R.J.E., Bosscha, K., van den Brekel, M.W.M., Petersen, J.F., Westerman, M., Honings, J., Takes, R.P., Houtenbos, I., van den Broek, W.T., de Bree, R., Jansen, P., Eerenstein, S.E.J., Leemans, C.R., Zijlstra, J.M., Cuijpers, P., van de Poll-Franse, L.V., Verdonck-de Leeuw, I.M.

Get full text

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma by Geurts, Y.M., Neppelenbroek, S.I.M., Aleman, B.M.P., Janus, C.P.M., Krol, A.D.G., van Spronsen, D.J., Plattel, W.J., Roesink, J.M., Verschueren, K.M.S., Zijlstra, J.M., Koene, H.R., Nijziel, M.R., Schimmel, E.C., de Jongh, E., Ong, F., te Boome, L.C.J., van Rijn, R.S., Böhmer, L.H., Ta, B.D.P., Visser, H.P.J., Posthuma, E.F.M., Bilgin, Y.M., Muller, K., van Kampen, D., So-Osman, C., Vermaat, J.S.P., de Weijer, R.J., Kersten, M.J., van Leeuwen, F.E., Schaapveld, M.

Get full text